The company's September quarter profit surged 120% year-on-year, driven by a 34% revenue jump and significant operating leverage.
Bafna Pharmaceuticals reported a 120% surge in net profit for Q2 FY27, reaching ₹6.85 crore. Revenue grew 34% to ₹47.67 crore, with the net profit margin expanding to 14.4% from 8.8% a year ago.
For Bafna Pharmaceuticals, the September quarter was a sharp recovery from a muted June period, turning strong sales into even stronger profits. The company’s net profit more than doubled year-on-year, reaching ₹6.85 crore, as revenue jumped 34% to ₹47.67 crore.
The numbers show a clear shift. While revenue grew robustly, total expenses rose at a slower 25% pace, creating significant operating leverage. This pushed the net profit margin to 14.4%, a 560 basis point improvement from the same quarter last year.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 (Sep 2026) | PreviousQ1 FY27 (Jun 2026) |
|---|---|---|
| Revenue (₹ Cr) | 47.67 | 26.58 |
| Profit (₹ Cr) | 6.85 | 0.07 |
| Net Profit Margin (%) | 14.4 | 0.3 |
The margin expansion was driven by disciplined cost management. According to a report by scanx.trade, the cost of materials consumed rose only 9.8% year-on-year, far slower than the 34% revenue growth. This divergence was the key driver behind the profit surge.
Higher depreciation and interest costs, up 27% and 18% respectively, reflect ongoing capital expenditure. The company’s total assets grew to ₹193 crore by September 2026 from ₹175.5 crore in March, indicating investment in capacity.
This expansion is consuming cash. Scanx.trade notes that while operations generated ₹10 crore in cash over the half-year, investing activities used ₹8.9 crore, primarily for capex. Trade receivables and inventories also rose, signaling higher working capital needs.
Live Chart
· BAFNAPH
(BSE)
ISIN: INE878I01022
Management, as cited by StockFin.ai, is focused on strategic expansion into regulated markets and maintaining a minimum-debt status. The company aims for an EBITDA margin of at least 15%, a target it exceeded this quarter with an 18% margin reported by sahi.com.
Key Points
The quarter demonstrates Bafna Pharma’s ability to convert top-line momentum into bottom-line gains through cost control. The challenge is sustaining this margin profile as the company invests for growth, which is already evident in rising capital expenditure and working capital.
The focus on regulated markets and a target EBITDA margin above 15% provides a clear benchmark. Execution on new product filings and managing the balance between growth investment and financial discipline will determine if this quarter’s performance is a new baseline or a peak.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.